M&A / Deals Acquisitive Lilly offers $2.88bn for Merida Bio PharmaphorumLilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.Immunology & InflammationRead full story pharminent August 31, 2026 (Last updated: September 1, 2026) Pharmaphorum Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida. Immunology & Inflammation Read full story Post navigation Previous: FDA Approves Mounjaro Label Expansion to Reduce Cardiovascular Risk in Type 2 DiabetesNext: ESC 2026: Evolocumab explores new frontiers in CV disease prevention Related Stories M&A / Deals McKesson to acquire Precision Medicine Group for $2.25bn pharminent August 26, 2026 M&A / Deals China’s Haisco forms immunology biotech with up to $1.5B from American VCs pharminent August 25, 2026 M&A / Deals Roche commits to lean-mass preservation with Hanmi obesity deal pharminent August 24, 2026
